WO2017151940A3 - Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation - Google Patents

Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation Download PDF

Info

Publication number
WO2017151940A3
WO2017151940A3 PCT/US2017/020480 US2017020480W WO2017151940A3 WO 2017151940 A3 WO2017151940 A3 WO 2017151940A3 US 2017020480 W US2017020480 W US 2017020480W WO 2017151940 A3 WO2017151940 A3 WO 2017151940A3
Authority
WO
WIPO (PCT)
Prior art keywords
present disclosure
modulatory multimeric
cell
polypeptides
cell modulatory
Prior art date
Application number
PCT/US2017/020480
Other languages
English (en)
Other versions
WO2017151940A2 (fr
Inventor
III Ronald D. SEIDEL
Rodolfo CHAPARRO
Original Assignee
Cue Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma, Inc. filed Critical Cue Biopharma, Inc.
Priority to KR1020187028429A priority Critical patent/KR20180132070A/ko
Priority to US16/077,303 priority patent/US20190046648A1/en
Priority to CN201780027393.7A priority patent/CN109414498A/zh
Priority to EP17760833.8A priority patent/EP3423078A4/fr
Priority to JP2018546577A priority patent/JP7372036B2/ja
Priority to CA3014466A priority patent/CA3014466A1/fr
Priority to AU2017225787A priority patent/AU2017225787B2/en
Publication of WO2017151940A2 publication Critical patent/WO2017151940A2/fr
Publication of WO2017151940A3 publication Critical patent/WO2017151940A3/fr
Priority to IL261402A priority patent/IL261402A/en
Priority to US17/958,904 priority patent/US20230330235A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)

Abstract

La présente invention concerne des polypeptides immunomodulateurs variants et des polypeptides de fusion comprenant les peptides immunomodulateurs variants. La présente invention concerne des polypeptides multimères modulateurs des lymphocytes T et des compositions les comprenant, les polypeptides multimères modulateurs des lymphocytes T comprenant un polypeptide immunomodulateur variant de la présente invention. La présente invention concerne des acides nucléiques comprenant des séquences nucléotidiques codant pour les polypeptides multimères modulateurs des lymphocytes T ; et des cellules hôtes comprenant les acides nucléiques. La présente invention concerne des procédés de modulation de l'activité d'un lymphocyte T ; les procédés comprennent la mise en contact du lymphocyte T avec un polypeptide multimère modulateur des lymphocytes T de la présente invention.
PCT/US2017/020480 2016-03-03 2017-03-02 Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation WO2017151940A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020187028429A KR20180132070A (ko) 2016-03-03 2017-03-02 T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US16/077,303 US20190046648A1 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof
CN201780027393.7A CN109414498A (zh) 2016-03-03 2017-03-02 T细胞调节性多聚体多肽及其使用方法
EP17760833.8A EP3423078A4 (fr) 2016-03-03 2017-03-02 Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation
JP2018546577A JP7372036B2 (ja) 2016-03-03 2017-03-02 Ｔ細胞調節多量体ポリペプチド及びその使用方法
CA3014466A CA3014466A1 (fr) 2016-03-03 2017-03-02 Polypeptides multimeres modulateurs des lymphocytes t et leurs procede d'utilisation
AU2017225787A AU2017225787B2 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof
IL261402A IL261402A (en) 2016-03-03 2018-08-27 T cell modulatory multimeric polypeptides and methods of using them
US17/958,904 US20230330235A1 (en) 2016-03-03 2022-10-03 T-cell modulatory multimeric polypeptides and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303268P 2016-03-03 2016-03-03
US62/303,268 2016-03-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/077,303 A-371-Of-International US20190046648A1 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof
US17/958,904 Continuation US20230330235A1 (en) 2016-03-03 2022-10-03 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2017151940A2 WO2017151940A2 (fr) 2017-09-08
WO2017151940A3 true WO2017151940A3 (fr) 2017-10-12

Family

ID=59743280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/020480 WO2017151940A2 (fr) 2016-03-03 2017-03-02 Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation

Country Status (9)

Country Link
US (2) US20190046648A1 (fr)
EP (1) EP3423078A4 (fr)
JP (1) JP7372036B2 (fr)
KR (1) KR20180132070A (fr)
CN (1) CN109414498A (fr)
AU (1) AU2017225787B2 (fr)
CA (1) CA3014466A1 (fr)
IL (1) IL261402A (fr)
WO (1) WO2017151940A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015013557B1 (pt) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
KR20190019068A (ko) * 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
DK3558339T3 (da) 2016-12-22 2024-02-26 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
WO2018129474A1 (fr) 2017-01-09 2018-07-12 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CA3062591A1 (fr) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Vecteurs neoantigeniques alphaviraux
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
WO2019051127A1 (fr) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. Polypeptide multimère modulateur de lymphocyte t ayant des sites de conjugaison et procédés d'utilisation associés
EP3737689A4 (fr) * 2018-01-09 2021-12-01 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
CN112351793A (zh) * 2018-05-23 2021-02-09 磨石肿瘤生物技术公司 免疫检查点抑制剂共表达载体
JP2022522404A (ja) * 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
CA3137463A1 (fr) * 2019-05-29 2020-10-03 Cue Biopharma, Inc. Polypeptides modulateurs de lymphocytes t multimeres et leurs procedes d'utilisation
KR20220016137A (ko) 2019-05-30 2022-02-08 그릿스톤 바이오, 인코포레이티드 변형된 아데노바이러스
CN114450305A (zh) * 2019-06-05 2022-05-06 天演药业公司 抗cd137l抗体及其使用方法
MX2022003367A (es) * 2019-09-20 2022-04-11 Cue Biopharma Inc Polipeptidos moduladores de linfocitos t y metodos de uso de estos.
CA3169949A1 (fr) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Polypeptides multimeres modulateurs de lymphocytes t et leurs methodes d'utilisation
JP2023541108A (ja) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド マルチエピトープワクチンカセット
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
EP4211149A1 (fr) * 2020-09-09 2023-07-19 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation
US20240092899A1 (en) * 2021-02-07 2024-03-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody
WO2024088404A1 (fr) * 2022-10-28 2024-05-02 Fbd Biologics Limited Variants de 4-1bbl modifiés et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038349A1 (en) * 2001-07-27 2004-02-26 Hilbert David M. Heteromultimeric TNF ligand family members
US20040209363A1 (en) * 2001-07-12 2004-10-21 Tania Watts Methods and compositions for modulating T cell activation and uses thereof
WO2015195531A2 (fr) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Polypeptides syntac et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0905253A3 (fr) 1992-12-03 2000-11-02 Genzyme Corporation Vecteur adenovira délété de tous les ORF de E4 excepté ORF6
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
WO2007087503A1 (fr) * 2006-01-23 2007-08-02 Novozymes A/S Polypeptides a activité lipase et polynucléotides codant lesdits polypeptides
CN102898504B (zh) * 2012-10-23 2014-08-06 中国农业大学 抗氧化活性合成肽及其用途
US9914759B2 (en) 2013-07-19 2018-03-13 Vib Vzw Targeted modified TNF family members
WO2016029043A1 (fr) * 2014-08-21 2016-02-25 The General Hospital Corporation Mutéines de ligands de la superfamille du facteur de nécrose tumorale (tnfsf) et de ligands de type tnf et leurs procédés de préparation et d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209363A1 (en) * 2001-07-12 2004-10-21 Tania Watts Methods and compositions for modulating T cell activation and uses thereof
US20040038349A1 (en) * 2001-07-27 2004-02-26 Hilbert David M. Heteromultimeric TNF ligand family members
WO2015195531A2 (fr) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Polypeptides syntac et leurs utilisations

Also Published As

Publication number Publication date
IL261402A (en) 2018-10-31
JP7372036B2 (ja) 2023-10-31
EP3423078A2 (fr) 2019-01-09
US20230330235A1 (en) 2023-10-19
US20190046648A1 (en) 2019-02-14
WO2017151940A2 (fr) 2017-09-08
AU2017225787B2 (en) 2021-09-23
CN109414498A (zh) 2019-03-01
CA3014466A1 (fr) 2017-09-08
AU2017225787A1 (en) 2018-08-30
JP2019512222A (ja) 2019-05-16
KR20180132070A (ko) 2018-12-11
EP3423078A4 (fr) 2019-11-06

Similar Documents

Publication Publication Date Title
WO2017151818A3 (fr) Polypeptides multimères modulateurs des lymphocytes t et leurs procédés d'utilisation
WO2017151940A3 (fr) Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
MX2017010721A (es) Interruptores transcripcionales activados mediante unión y métodos para su uso.
EP4219702A3 (fr) Variants d'enzymes et polynucléotides codant pour ces variants
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
MX2022001134A (es) Proteinas quimericas de factor viii y usos de estas.
EP3775192A4 (fr) Constructions polypeptidiques de lysine-peptide antimicrobien (amp), lysines, polynucléotides isolés les codant et utilisations correspondantes
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
WO2020061376A3 (fr) Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
EP3840771A4 (fr) Constructions polypeptidiques de lysine-peptide antimicrobien (amp), lysines, polynucléotides isolés les codant et leurs utilisations
WO2016130628A8 (fr) Mutants de griffithsine
WO2015185758A3 (fr) Préparation comprenant le facteur viii et des peptides du facteur de von willebrand
AU2021214163A1 (en) Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EA201591609A1 (ru) Варианты альфа-амилазы
WO2014152247A8 (fr) Protéines de liaison au tnf améliorées
WO2015120542A8 (fr) Protéines hybrides et leurs utilisations
WO2016036635A8 (fr) Gènes de chromobacterium subtsugae
WO2016160976A3 (fr) Protéines de liaison au tnf monovalentes
WO2015077506A3 (fr) Identification d'une nouvelle cytokine de cellules bêta
EA201991195A1 (ru) Мультимерные полипептиды, модулирующие т-клетки, и способы их применения

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 3014466

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 261402

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017225787

Country of ref document: AU

Date of ref document: 20170302

Kind code of ref document: A

Ref document number: 2018546577

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187028429

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017760833

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017760833

Country of ref document: EP

Effective date: 20181004

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17760833

Country of ref document: EP

Kind code of ref document: A2